| S8591 |
FX1
|
FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. This compound shows great selectivity against a panel of 50 different kinases. 10 μM of this chemical fails to significantly inhibit of any of these kinases. It induces apoptosis.
|
-
Front Immunol, 2025, 16:1558845
-
Victoria University of Wellington, 2023,
-
Haematologica, 2022, 10.3324/haematol.2022.280879
|
|
| S6937 |
BI-3802
|
BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. This compound inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. It exhibits antitumor activity.
|
-
Adv Sci (Weinh), 2025, 12(31):e01284
-
Phytomedicine, 2024, 133:155944
-
Haematologica, 2022, 10.3324/haematol.2022.280879
|
|
| S8735 |
BI-3812
|
BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
|
-
Haematologica, 2022, 10.3324/haematol.2022.280879
-
bioRxiv, 2022, 10.1101/2022.11.03.514941
|
|
| S8250 |
79-6 (CID5721353)
|
79-6 (CID5721353), a BCL6 inhibitor, has a Kd value of 138 μM.
|
-
Cell Rep Med, 2022, 3(9):100744
|
|